Navigation Links
Panacea Pharmaceuticals Presents Three Papers Regarding Its Nanoparticle-Based Therapeutic Cancer Vaccine at the Society for Immunotherapy of Cancer Annual Meeting at National Harbor, MD
Date:11/8/2013

GAITHERSBURG, Md., Nov. 8, 2013 /PRNewswire-iReach/ -- Panacea Pharmaceuticals, Inc. presents three papers regarding its Nanoparticle-Based Therapeutic Cancer Vaccine at the Society for Immunotherapy of Cancer Annual Meeting at National Harbor, MD held November 8-10, 2013.  The three papers are titled:

Design, Development and Production of Nano-Particle-Based Anticancer Vaccine Targeting Human Aspartyl (Asparaginyl) β-Hydroxylase (HAAH)

Immunogenicity of a Lambda Phage-Based Anti-Cancer Vaccine Targeting HAAH

Inhibition of Tumor Growth in vivo by a Nanoparticle-Based Therapeutic Cancer Vaccine Targeting HAAH

(Photo: http://photos.prnewswire.com/prnh/20131108/MN13284)

Panacea has chosen to target the HAAH molecule for its proprietary therapeutic cancer vaccine because HAAH is expressed on cancer cells and not on non-cancer cells and its function is consistent with the etiology of cancer, i.e., is associated with growth, motility and invasiveness of cancer cells.  Monoclonal antibodies to HAAH have proven to have efficacy in both in vitro and in vivo tumor models.  HAAH is, however, an embryonic antigen, and as such, presents self-antigen tolerance.  The present vaccine entity is designed to overcome this tolerance by altering the presentation of the antigen and by providing an immunostimulant.  The nanoparticle is neutralized bacteriophage construct containing portions of HAAH, is easy to produce and is generally regarded as safe.  The nanoparticle vaccine carries 200-300 copies of HAAH fragments of approximately 25 kDa molecular weight on its surface.  The nanoparticle vaccine also contains DNA fragments that present the phage CpG motif to activate the MHC class II pathway.  We have engineered and manufactured the nanoparticle vaccine to meet FDA requirements for human use.

The nanoparticle therapeutic cancer vaccine targeting HAAH is clearly immunogenic in mice despite the high degree of homology to the human protein that makes the AAH resemble a self-antigen.  All three HAAH-lambda constructs were immunogenic and the antibody response was dose-dependent.  The nanoparticle therapeutic cancer vaccine targeting HAAH is effective in inhibition of tumor growth in mice under various conditions.  Each of the three constructs can inhibit tumor growth.  The vaccine can slow the growth of tumors prophylactically or by treatment simultaneous with or subsequent to establishment of solid tumors.

"We are excited to report that the nanoparticle-based therapeutic cancer vaccine targeting HAAH can be manufactured readily and is effective in tumor models", said Hossein Ghanbari, Ph.D., CEO and CSO of Panacea.  "The HAAH phage constructs are now being developed as clinical candidate vaccines and we are taking all the steps to prepare for an IND submission to FDA", said Steven Fuller, Ph.D., COO of Panacea.

Media Contact: Hossein Ghanbari, Panacea Pharmaceuticals, Inc., 240-305-4601, hag@panaceapharma.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Panacea Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2013 Financial Results
2. ANI Pharmaceuticals Reports Net Revenues of $7.8 million, adjusted Non-GAAP EBITDA of $1.7 Million, and EPS of $0.13 for the Third Quarter Ended September 30, 2013
3. Vanda Pharmaceuticals Reports Third Quarter 2013 Results
4. Questcor Pharmaceuticals to Present at the 2013 Credit Suisse Annual Healthcare Conference
5. Imprimis Pharmaceuticals Inc. Announces Shift in Strategic Direction
6. Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2013 Financial Results
7. Cadence Pharmaceuticals Reports Third Quarter 2013 Financial Results
8. AcelRx Pharmaceuticals Reports Third Quarter 2013 Financial Results
9. Cumberland Pharmaceuticals Reports Third Quarter Financial Results
10. Jazz Pharmaceuticals Announces Third Quarter 2013 Financial Results
11. Top Trial Firm Cohen, Placitella & Roth, PC Investigating Ariad Pharmaceuticals, Inc., for Suspending Sales of its Leukemia Drug Iclusig
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... BRISBANE, Australia , Feb. 23, 2017  Directors from Pharma ... the two companies have joined forces, resulting in the founding of ... . Pharma To Market are pleased to announce their ... an office in Singapore . The company are ... Consulting as Co-Director of the Singapore based ...
(Date:2/24/2017)... -- Xynomic Pharmaceuticals, Inc., an oncology drug research and ... exclusive worldwide rights to develop, manufacture and commercialize ... hematological and solid tumors. To date ... clinical trials of Abexinostat in US, EU and ... completed, demonstrating that Abexinostat is clinically active in ...
(Date:2/23/2017)... 2017 LG Innotek hat heute die weltweit ... beträgt das 1,5-fache des 45-mW-Moduls der Konkurrenz. ... 200 und 280 nm und eignet sich damit für Sterilisationsaufgaben. ... DNA zerstört. Das Produkt von LG Innotek erzeugt UV-Strahlung ... ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... In the Health Care IT campaign, Robert Herjavec ... it’s not if you will be attacked, but when.” However, he and many others ... health care. , Improvements in auditing and monitoring have taken security in health care ...
(Date:2/24/2017)... ... 2017 , ... The narrative in “ Signal 8: An Australian Paramedic’s Story ... his paramedic experiences. Schanssema describes the tragedies he saw, as well as his struggles ... , Schanssema, initially unsure of the career path he wanted to take, found fulfillment ...
(Date:2/24/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, ... Yisrayl makes an astounding statement when he says that the entire Bible was ... details the current times so plainly that anyone should be able to see the ...
(Date:2/24/2017)... Farifax, VA (PRWEB) , ... February 24, 2017 , ... ... winners for excellence in radiology marketing programs at the annual Building Better ... the Worthington Renaissance Fort Worth Hotel in Fort Worth, Texas. Nine awards are given ...
(Date:2/24/2017)... ... February 24, 2017 , ... Castle Farms, the ... Military Wedding Giveaway, with the winning couple announced on Feb. 14, 2017, on ... donated from local vendors: A Matter of Taste, Ryan Rousseau Enterprises, A Touch ...
Breaking Medicine News(10 mins):